CTR86 Antibody

What is CD86 and what role does it play in the immune system?

CD86 (also known as B7-2) is a type I membrane protein and member of the immunoglobulin superfamily that functions as a critical costimulatory molecule in the immune system. It serves as one of two ligands (the other being CD80) for CTLA-4 and CD28 receptors on T cells. CD86 plays an essential role in the costimulatory signal required for T-lymphocyte proliferation and interleukin-2 production through its binding to CD28 or CTLA-4 . It is particularly crucial in the early events of T-cell activation and in determining whether naive T-cells develop immunity or anergy, a decision typically made within 24 hours after activation . Beyond T-cell regulation, CD86 is also involved in B cell function and helps regulate IgG1 production levels . The absence of sufficient costimulation involving CD86 can induce immune tolerance rather than activation, highlighting its regulatory importance in immune responses .

How does CD86 differ from CD80 in immune function?

While CD86 and CD80 both serve as ligands for CD28 and CTLA-4, evidence suggests they play distinct roles in T helper cell differentiation . CD86 appears to be more prominently involved in the initial immune response and is expressed earlier and at higher levels than CD80 on antigen-presenting cells following activation. The differential expression patterns and binding kinetics of these two costimulatory molecules create a temporal regulation system for T cell responses. CD86 has been shown to have a more crucial role in the early phase of the immune response, while CD80 may be more important for sustaining ongoing immune reactions or regulating their resolution . This understanding is essential for researchers designing experiments that target specific phases of the immune response.

Which cell types primarily express CD86?

CD86 is predominantly expressed on professional antigen-presenting cells (APCs), including dendritic cells, macrophages, and B lymphocytes . Its expression can be upregulated upon activation of these cells during an immune response. CD86 expression on these APCs is critical for their ability to effectively present antigens to T cells and provide the necessary costimulatory signals for T cell activation. In flow cytometry studies, CD86 is often detected on CD14+ human peripheral blood monocytes, demonstrating its expression on this cell population . Additionally, CD86 has been detected in human Burkitt's lymphoma cell lines such as Daudi and Ramos, making these useful positive controls for CD86 expression studies .

What are the main applications of CD86 antibodies in immunological research?

CD86 antibodies serve multiple crucial functions in immunological research, with applications spanning various techniques:

Western Blot Analysis: CD86 antibodies can detect the protein at approximately 74-75 kDa under reducing conditions . This application is valuable for confirming CD86 expression in cell lysates and validating knockout models. For optimal results, researchers should use immunoblot buffer Group 1 and PVDF membranes when performing Western blots for CD86 detection .

Flow Cytometry: CD86 antibodies are extensively used to identify and quantify antigen-presenting cells and analyze their activation status. They can be effectively used to detect CD86 on peripheral blood monocytes, B cells, and cell lines such as Ramos . For optimal staining, researchers should follow protocols specific for membrane-associated proteins and use appropriate secondary antibodies conjugated to fluorophores like PE or APC .

Immunohistochemistry (IHC): CD86 antibodies can visualize the distribution and localization of CD86 in tissue sections, providing spatial context to its expression patterns in different physiological and pathological conditions .

Functional Blocking Studies: Neutralizing CD86 antibodies can block the interaction between CD86 and its receptors (CD28/CTLA-4), allowing researchers to study the functional consequences of disrupting this pathway in various immune responses . The neutralization dose (ND50) is typically 0.5-2.5 μg/mL in the presence of 2 μg/mL Recombinant Human B7-2/CD86 Fc Chimera .

T Cell Activation Assays: CD86 antibodies can be used in assays measuring IL-2 secretion following T cell activation, helping researchers understand the functional impact of CD86 in T cell stimulation .

How should I validate the specificity of a CD86 antibody?

Rigorous validation of CD86 antibody specificity is crucial for obtaining reliable research results. A comprehensive validation approach should include:

Positive and Negative Controls: Use cell lines known to express CD86 (such as Daudi or Ramos lymphoma cells) as positive controls . For negative controls, utilize CD86 knockout cell lines, as demonstrated in the Western blot validation showing detection of a 74 kDa band in parental Ramos cells but not in CD86 knockout Ramos cells . Additionally, isotype controls (such as Mouse IgG1) should be included to identify any non-specific binding .

Multiple Detection Methods: Confirm specificity across different techniques (Western blot, flow cytometry, IHC) when possible, as each method provides different information about antibody specificity. For example, flow cytometry can confirm surface binding while Western blot confirms recognition of the denatured protein at the expected molecular weight .

Blocking Experiments: Perform pre-adsorption tests by incubating the antibody with recombinant CD86 protein before application to samples. Disappearance of signal indicates specificity for CD86.

Validation Across Species: If working with non-human samples, verify cross-reactivity or species specificity of the antibody before proceeding with experiments.

Antibody Titration: Perform serial dilutions of the antibody to determine the optimal concentration that gives the best signal-to-noise ratio, which helps minimize non-specific binding.

What are the optimal protocols for detecting CD86 using flow cytometry?

For optimal detection of CD86 using flow cytometry, researchers should follow these methodological guidelines:

Sample Preparation:

• For peripheral blood mononuclear cells (PBMCs): Isolate cells using density gradient centrifugation and maintain viability in appropriate buffer containing 1-2% protein (BSA or FBS) to minimize non-specific binding.

• For cell lines: Harvest cells in exponential growth phase to ensure consistent CD86 expression levels.

Staining Protocol:

• Wash 1×10^6 cells twice with flow cytometry buffer (PBS containing 2% FBS and 0.1% sodium azide).

• Block Fc receptors using 5% normal serum from the species in which the secondary antibody was raised, for 15-20 minutes at 4°C.

• For direct staining, add fluorophore-conjugated CD86 antibody at the manufacturer's recommended concentration (typically 5-10 μg/mL).

• For indirect staining, incubate with primary anti-CD86 antibody (such as Mouse Anti-Human B7-2/CD86 Monoclonal Antibody) followed by fluorophore-conjugated secondary antibody (such as Allophycocyanin-conjugated Anti-Mouse IgG) .

• Include appropriate isotype controls (e.g., Mouse IgG1 for mouse-derived anti-CD86 antibodies) .

• Incubate for 30 minutes at 4°C in the dark.

• Wash twice with flow cytometry buffer.

• Resuspend in 300-500 μL of flow cytometry buffer or fixative if analysis is delayed.

Multicolor Panel Design:
When designing multicolor panels including CD86, consider combining with markers like:

• CD14 to identify monocytes

• HLA-DR for activated antigen-presenting cells

• CD80 to examine the relationship between both costimulatory molecules

• CD40 or CD83 to assess activation status of dendritic cells

Data Analysis:

• Use fluorescence minus one (FMO) controls to set accurate gates

• Present data as percent positive cells and mean/median fluorescence intensity (MFI)

• For quantitative studies, consider using calibration beads to standardize measurements across experiments

How can CD86 antibodies be utilized in T cell activation and exhaustion studies?

CD86 antibodies serve as valuable tools in investigating the complex processes of T cell activation and exhaustion:

T Cell Activation Assays:
Researchers can use CD86 antibodies to study the role of this costimulatory molecule in T cell activation by either blocking or enhancing CD86 signaling. In functional assays, the neutralization of CD86 with specific antibodies can inhibit IL-2 secretion by T cells, allowing quantification of CD86's contribution to T cell activation . This approach helps distinguish between CD28/CD86-dependent and independent activation pathways.

A typical experimental setup would involve:

• Co-culturing antigen-presenting cells (expressing CD86) with T cells

• Adding varying concentrations of blocking anti-CD86 antibodies (typical neutralization dose: 0.5-2.5 μg/mL)

• Measuring T cell activation markers (CD69, CD25), proliferation, and cytokine production (particularly IL-2)

• Comparing results with CD80 blockade to disentangle the relative contributions of each costimulatory pathway

T Cell Exhaustion Research:
In chronic infections and cancer, T cells can enter a state of exhaustion characterized by diminished function and expression of inhibitory receptors. CD86 antibodies can help investigate:

• The relationship between costimulatory molecule expression (CD86) and inhibitory receptor expression (PD-1, CTLA-4) on antigen-presenting cells

• How CD86 expression levels on antigen-presenting cells correlate with the development of T cell exhaustion

• Whether restoring CD86 signaling can help reverse T cell exhaustion in combination with checkpoint inhibitor therapy

For these studies, researchers should consider using flow cytometry to simultaneously measure CD86 expression on antigen-presenting cells and exhaustion markers on T cells from the same samples, allowing for direct correlation analyses.

What are the considerations for using CD86 antibodies in studying the CTLA-4 pathway?

The CD86-CTLA-4 interaction represents a critical inhibitory pathway in immune regulation, and studying it requires special considerations:

Binding Competition:
CD86 binds both CD28 (costimulatory) and CTLA-4 (inhibitory), but with different affinities. CTLA-4 binds CD86 with approximately 20-fold higher affinity than CD28. When using CD86 antibodies in CTLA-4 pathway studies, researchers must consider whether the antibody epitope overlaps with the CTLA-4 binding site, as this would directly impact the interpretation of results. Ideally, researchers should characterize whether their CD86 antibody preferentially blocks interaction with CD28, CTLA-4, or both.

Temporal Expression Dynamics:
CTLA-4 is upregulated on T cells after activation, creating a time-dependent regulatory mechanism. When designing experiments to study the CD86-CTLA-4 pathway:

• Include time-course analyses to capture the dynamic nature of these interactions

• Consider using inducible systems to control the timing of CD86 or CTLA-4 expression

• Use flow cytometry to correlate CD86 expression on antigen-presenting cells with CTLA-4 expression on responding T cells at multiple time points

Receptor Clustering Effects:
CD86 can form clusters on the cell surface, which affects its interaction with receptors. Notably, isoform 2 of CD86 interferes with the formation of these clusters, acting as a negative regulator of T-cell activation . When studying the CTLA-4 pathway, researchers should consider:

• Which CD86 isoform predominates in their experimental system

• How receptor clustering might affect antibody binding and function

• Whether their CD86 antibody recognizes all relevant isoforms

Functional Readouts:
When studying the CTLA-4 pathway using CD86 antibodies, appropriate functional readouts include:

• T cell proliferation assays (CFSE dilution or 3H-thymidine incorporation)

• Regulatory T cell induction and function

• Cytokine production profiles (especially IL-10 and TGF-β for regulatory responses)

• Changes in the expression of downstream signaling molecules in the CTLA-4 pathway

How might CD86 expression correlate with circulating T follicular helper (Tfh) cells in infectious diseases?

Recent research on COVID-19 has revealed important relationships between costimulatory molecules like CD86 and specialized T cell subsets such as T follicular helper (Tfh) cells:

CXCR3+ Tfh Cells and Disease Severity:
Studies of COVID-19 patients have shown that individuals who experienced severe disease exhibited higher frequencies of CXCR3+ Tfh cells compared to those with non-severe disease . This finding suggests that costimulatory pathways, potentially including CD86-mediated interactions, may influence the development and expansion of specific Tfh cell subsets during infection.

Correlation with Antibody Responses:
Circulating Tfh cells are functionally important for antibody responses, and their frequencies positively associate with neutralizing antibody titers in COVID-19-convalescent individuals . Researchers investigating CD86's role in this process should consider:

• Analyzing CD86 expression on antigen-presenting cells in relation to Tfh cell frequencies

• Examining how blocking CD86 affects the development of spike-specific Tfh cells

• Investigating whether CD86 expression levels predict subsequent antibody responses

Methodological Approach for Correlation Studies:
To study correlations between CD86 expression and Tfh cells, researchers should implement:

• Multiparameter flow cytometry panels including:

  • CD86 and other costimulatory molecules on antigen-presenting cells

  • Tfh markers (CXCR5, PD-1, ICOS, BCL6) on T cells

  • CXCR3 to identify specific Tfh subsets associated with antibody responses

• Longitudinal sampling to track changes in CD86 expression and Tfh cell frequencies over the course of infection

• Functional assays measuring the ability of CD86-expressing antigen-presenting cells to induce Tfh differentiation in vitro

• Correlation analyses between CD86 expression levels, Tfh cell frequencies, and antibody titers

This approach would provide insights into how CD86-mediated costimulation contributes to protective immunity through the regulation of Tfh responses in infectious diseases.

What are common technical challenges when using CD86 antibodies in Western blotting?

Western blotting for CD86 presents several technical challenges that researchers should anticipate and address:

Variable Molecular Weight:
CD86 is heavily glycosylated, resulting in a higher apparent molecular weight (approximately 74-75 kDa) than predicted from its amino acid sequence alone (about 52 kDa) . Researchers may observe different band patterns depending on:

• Cell type (glycosylation patterns vary)

• Sample preparation methods (deglycosylation treatments will alter migration)

• Reducing vs. non-reducing conditions

Specific Protocol Recommendations:
For optimal CD86 detection by Western blot, researchers should:

• Use PVDF membrane rather than nitrocellulose for better protein retention

• Employ reducing conditions with Immunoblot Buffer Group 1

• Load adequate protein (minimum 20-30 μg of total cell lysate)

• Consider longer transfer times due to the relatively high molecular weight

• Include positive controls such as Daudi or Ramos cell lysates

Troubleshooting Weak or Absent Signals:
If CD86 detection is problematic, consider these solutions:

• Increase antibody concentration or incubation time

• Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

• Optimize blocking conditions (try different blocking agents)

• Verify protein expression levels in your sample (CD86 may be expressed at low levels in some cell types)

• Check for potential proteolytic degradation by including protease inhibitors

Verification of Specificity:
To confirm specific detection of CD86, researchers should:

• Include a CD86 knockout cell line as a negative control

• Use GAPDH or another housekeeping protein as a loading control

• Pre-adsorb the antibody with recombinant CD86 protein to demonstrate specific binding

How can I optimize CD86 antibody staining for immunohistochemistry?

Successful immunohistochemical detection of CD86 requires careful attention to several methodological details:

Tissue Preparation and Fixation:

• For formalin-fixed paraffin-embedded (FFPE) tissues:

  • Optimal fixation time in 10% neutral buffered formalin is 24 hours

  • Extended fixation may mask CD86 epitopes, necessitating more rigorous antigen retrieval

• For frozen sections:

  • Fix briefly in cold acetone or 4% paraformaldehyde

  • Process immediately or store at -80°C with desiccant

Antigen Retrieval Methods:
CD86 detection often requires antigen retrieval to unmask epitopes. Compare these methods for optimal results:

• Heat-induced epitope retrieval (HIER):

  • Citrate buffer (pH 6.0) at 95-100°C for 20 minutes

  • EDTA buffer (pH 9.0) if citrate buffer yields weak staining

• Enzymatic retrieval:

  • Proteinase K (10-20 μg/mL) for 10-15 minutes at room temperature

  • Particularly useful for heavily fixed tissues

Detection Systems:

• For low expression levels, use high-sensitivity detection systems:

  • Polymer-based detection systems

  • Tyramide signal amplification (TSA)

• For co-localization studies, consider multiplex immunofluorescence with CD86 and other markers

Controls and Validation:

• Positive tissue controls: Lymph nodes or tonsils (rich in antigen-presenting cells)

• Negative controls:

  • Isotype control antibody at the same concentration

  • Primary antibody omission

  • Tissue known to be negative for CD86

• Absorption controls: Pre-incubate antibody with recombinant CD86 protein

Troubleshooting Tips:

• Background staining: Increase blocking time (2-3 hours), use avidin/biotin blocking for biotin-based detection systems

• Weak staining: Try different antigen retrieval methods, increase antibody concentration or incubation time (overnight at 4°C)

• Non-specific staining: Dilute antibody further, reduce incubation temperature, include additional blocking steps

What controls should be included when using CD86 antibodies for functional studies?

Robust experimental design for functional studies using CD86 antibodies requires comprehensive controls:

Antibody-Specific Controls:

• Isotype Control Antibody: Include an irrelevant antibody of the same isotype, species, and format as the CD86 antibody . This controls for non-specific effects related to the antibody's constant regions.

• Concentration Matching: Ensure isotype controls are used at identical concentrations to CD86 antibodies.

• Fab or F(ab')2 Fragments: To distinguish between effects mediated by the antigen-binding region versus Fc-dependent effects, include controls with Fab fragments of CD86 antibodies.

• Validated Blocking Control: If available, use a well-characterized CD86 blocking antibody with established neutralizing activity as a positive control .

Pathway-Specific Controls:

• CD80 Blockade: Include parallel experiments blocking CD80 (the other ligand for CD28/CTLA-4) to distinguish between CD86-specific and redundant costimulatory effects.

• CD28 or CTLA-4 Blockade: Block the receptors rather than the ligand to confirm the pathway's involvement.

• Recombinant Proteins: Include soluble CD86 protein as a competitive inhibitor to compare with antibody-mediated blocking.

Cellular Controls:

• CD86 Knockdown/Knockout Cells: Use cells with genetically reduced or eliminated CD86 expression as a gold standard for complete CD86 inhibition .

• Titration Controls: Perform dose-response experiments with varying concentrations of CD86 antibodies to establish the relationship between degree of blocking and functional effect.

• Timing Controls: Add CD86 antibodies at different time points in the experiment to distinguish between effects on initiation versus maintenance of responses.

Functional Readout Controls:

• Positive Functional Control: Include a stimulus known to be independent of CD86 (e.g., PMA/ionomycin for T cell activation) to confirm cellular responsiveness.

• Multiple Readouts: Measure several parameters (e.g., proliferation, cytokine production, marker expression) to comprehensively assess functional effects.

• Time Course Analysis: Collect data at multiple time points to capture transient effects and distinguish between delayed versus inhibited responses.

How do DNA encoded monoclonal antibodies (DMAbs) technology relate to CD86 research?

The emerging DNA encoded monoclonal antibodies (DMAbs) technology presents innovative opportunities for CD86 research and therapeutic applications:

DMAb Technology Overview:
DMAbs represent a novel approach where DNA sequences encoding monoclonal antibodies are delivered directly to cells, enabling in vivo antibody production . Recent clinical trials have demonstrated promising results, including durable antibody expression for up to 72 weeks without developing anti-drug antibodies (ADAs) . This technology could potentially overcome limitations associated with conventional monoclonal antibody administration, such as short half-life and immunogenicity.

Potential Applications in CD86 Research:

• Long-term Modulation Studies: DMAbs encoding anti-CD86 antibodies could enable studies of prolonged CD86 blockade without repeated dosing, providing insights into chronic modulation of this pathway.

• Local Expression Models: By delivering DMAbs encoding anti-CD86 antibodies to specific tissues, researchers could investigate tissue-specific effects of CD86 blockade.

• Combination with Checkpoint Inhibitors: The DMAb platform could allow simultaneous expression of anti-CD86 antibodies alongside other immune checkpoint modulators, facilitating combination therapy investigations.

Methodological Considerations:

When considering applying DMAb technology to CD86 research, researchers should account for:

• Expression Kinetics: DMAb-derived antibody levels may take time to accumulate, unlike immediate availability with recombinant protein administration. This requires careful experimental timing and monitoring of antibody levels.

• Delivery Methods: The effectiveness of DMAb approaches depends on efficient DNA delivery to target cells, requiring optimization of delivery methods (electroporation, nanoparticles, etc.).

• Validation: Before functional studies, researchers must confirm:

  • In vivo expression of the anti-CD86 antibody

  • Binding specificity to CD86

  • Functional neutralizing capacity

• Monitoring: Include regular serum sampling to quantify anti-CD86 antibody levels throughout long-term experiments.

The advantages of this approach include sustained antibody expression without developing anti-drug antibodies, potentially providing more consistent neutralization than intermittent dosing with conventional antibodies . This technology could be particularly valuable for studying chronic modulation of CD86-dependent pathways in long-term disease models.

How might CD86 antibodies contribute to emerging immunotherapy approaches?

CD86 antibodies hold significant potential for advancing immunotherapy approaches through multiple mechanisms:

Combination with Checkpoint Inhibitors:
The CD86-CD28/CTLA-4 pathway intersects with other immune checkpoint pathways like PD-1/PD-L1. Strategic combinations of CD86-targeting approaches with established checkpoint inhibitors could provide synergistic effects by simultaneously releasing multiple brakes on the immune system. Researchers should explore:

• Timing and sequencing of anti-CD86 with anti-PD-1 or anti-CTLA-4 therapies

• Cell type-specific effects of these combinations on dendritic cells, T cells, and regulatory T cells

• Development of bispecific antibodies targeting CD86 and other checkpoint molecules

Targeted Delivery Approaches:
Advanced antibody engineering could enable targeted modulation of CD86 signaling in specific cell populations or tissues:

• Antibody-drug conjugates targeting CD86+ cells

• Bispecific antibodies linking CD86 to tumor-associated antigens

• Cell type-specific delivery systems for DNA-encoded anti-CD86 antibodies using the emerging DMAb technology

Modulating CD86 in CAR-T Cell Therapy:
CD86-directed approaches could enhance chimeric antigen receptor (CAR) T cell therapies through:

• Engineering CAR-T cells to express CD86 to enhance their persistence and function

• Using CD86 antibodies to modulate interactions between CAR-T cells and antigen-presenting cells

• Developing regulatory circuits in CAR-T cells that respond to CD86 signaling

Scientific Questions to Address:
To advance these approaches, researchers should prioritize understanding:

• The impact of CD86 modulation on different T cell subsets (effector, memory, regulatory, exhausted)

• Differential effects of targeting CD86 versus its receptors (CD28, CTLA-4)

• Optimal timing for CD86 modulation in the cancer immunity cycle

• Biomarkers that predict response to CD86-targeted interventions

What emerging techniques might enhance CD86 antibody characterization and applications?

Several cutting-edge techniques are poised to revolutionize CD86 antibody research:

Single-Cell Technologies:
Single-cell RNA sequencing combined with protein detection (CITE-seq) allows simultaneous measurement of CD86 expression and transcriptional profiles at the single-cell level. This approach can reveal:

• Heterogeneity in CD86 expression within seemingly homogeneous cell populations

• Transcriptional consequences of CD86 engagement in individual cells

• Identification of novel cell subsets defined by CD86 expression patterns

Advanced Imaging Techniques:
Super-resolution microscopy and multiplexed ion beam imaging (MIBI) can provide unprecedented spatial information about CD86 distribution:

• Nanoscale organization of CD86 molecules on the cell surface

• Co-localization with receptors and signaling components

• Tissue-level expression patterns with subcellular resolution

• Dynamic changes in CD86 clustering upon receptor engagement

Antibody Engineering and Benchmarking:
Recent advances in antibody engineering and characterization methods can enhance CD86 antibody quality and specificity:

• AI-driven antibody design targeting specific CD86 epitopes

• High-throughput screening using antibody display technologies

• Benchmarking antibody performance using standardized datasets and clustering methods

• Development of recombinant antibody formats with optimized properties

Structural Biology Approaches:
Cryo-electron microscopy and X-ray crystallography can provide detailed insights into CD86-antibody interactions:

• Epitope mapping with atomic resolution

• Structural basis for differential blocking of CD28 versus CTLA-4 binding

• Conformational changes induced by antibody binding

By integrating these advanced techniques, researchers can develop more precise tools for CD86 targeting and gain deeper insights into the fundamental biology of this important costimulatory molecule, ultimately advancing both basic research and therapeutic applications.